Continued treatment for thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study offers continued treatment with an investigational drug for people who completed a prior clinical trial for thyroid eye disease but still have bulging eyes (proptosis) or experienced a relapse. The goal is to provide ongoing care and monitor safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You completed the 24-week treatment period in one of the prior studies (MHB018A-P-301 or MHB018A-P-302).
- Your eye bulging did not improve enough or got worse, or you had a relapse during the safety follow-up.
- You do not need urgent eye surgery and are not planning corrective surgery or orbital radiation during the study.
- If you have diabetes, it must be well-controlled and stable.
- You must agree to use reliable birth control if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a longer-term use of MHB018A for people with thyroid eye disease who did not fully respond to treatment in a previous study. It aims to see if further treatment can help improve eye bulging and other symptoms.
This trial tests a new medication for people with long-term thyroid eye disease that has lasted over a year. The aim is to see if it can reduce symptoms like bulging and discomfort.
This trial tests a new medicine called MHB018A for people with active thyroid eye disease (TED), a condition that causes the eyes to bulge and become inflamed. The study aims to see if the drug can reduce symptoms and improve eye appearance compared to a placebo.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
This study tests a new medication called GenSci098 for people with active thyroid eye disease. It aims to reduce eye symptoms like redness, swelling, and bulging, and improve quality of life.
This trial compares a newer medication (teprotumumab) with standard steroid treatment for people with thyroid eye disease and vision loss who are about to have urgent surgery to relieve pressure on the optic nerve. The goal is to see which approach better protects and restores vision after surgery.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.